CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Eli Lilly and Company (LLY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Eli Lilly and Company (LLY)

Pharmaceutical Preparations · market cap $1089.7B · as of 2026-07-08

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-01 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Eli Lilly and Company (LLY) is a large-cap multinational pharmaceutical company with ~$1.13T market capitalization, anchored by explosive revenue growth driven primarily by GLP-1/incretin franchise assets. The company generated $65.2B in revenue in 2025, up from $45.0B in 2024 and $34.1B in 2023, with a sprawling late-stage pipeline including Retatrutide (obesity), Orforglipron (oral GLP-1), Remternetug (Alzheimer's), and Insulin Efsitora Alfa (diabetes). Key near-term catalysts include Phase 3 Baricitinib data (est. September 2026), Retatrutide Phase 3 readout (est. December 2026), and two Orforglipron Phase 3 readouts (est. Q1 2027).
The catalyst path
  • 2026-12-01 (est.)Phase 2 · Abemaciclibimp 7/10
  • 2026-12-02 (est.)Phase 2 · Necitumumabimp 7/10
  • 2026-12-15 (est.)Phase 2 · Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamideimp 7/10
  • 2027-01-01 (est.)Otherimp 3/10
  • 2027-02-15 (est.)Phase 2 · Brenipatideimp 7/10
  • 2027-02-28 (est.)Phase 2 · Pirtobrutinibimp 7/10
  • 2027-03-15 (est.)Phase 2 · Solbinsiranimp 7/10
  • 2027-03-20 (est.)Phase 2 · Niraparib Tosylate Monohydrateimp 7/10
Pipeline
AssetPhaseIndication
somatropin, rDNA origin, for injectionPhase 3Growth Disorder
RetatrutidePhase 3Obesity
Ultra-Rapid LisproPhase 3Type 1 Diabetes Mellitus
Erbitux (Cetuximab)Phase 2Colorectal Neoplasms
Atomoxetine HydrochloridePhase 3Attention Deficit Hyperactivity Disorder
LY2216684Phase 3Major Depressive Disorder
Insulin Efsitora AlfaPhase 3Type 2 Diabetes
AbemaciclibPhase 3Breast Cancer
LY2140023Phase 2Schizophrenia
LY3209590Phase 2Type 2 Diabetes Mellitus
LY3819253Phase 3COVID-19
LY900014Phase 3Type 1 Diabetes Mellitus
Ixekizumab Auto-InjectorPhase 3Plaque Psoriasis
GEMZARPhase 3Pancreatic Neoplasms
DulaglutidePhase 3Type 2 Diabetes Mellitus
IMC-1121B (ramucirumab)Phase 2Carcinoma, Non-Small-Cell Lung
LY2605541Phase 3Type 1 Diabetes Mellitus
BaricitinibPhase 3Systemic Juvenile Idiopathic Arthritis
GalcanezumabPhase 3Chronic Migraine
IxekizumabPhase 3Psoriasis
Price & technical context
3-month
+10.5%
6-month
+38.5%
12-month
+38.0%
52-wk range
$851.21–$1443.50
vs 50-day MA
+12.9%
vs 200-day MA
+27.1%
Realized vol
34.9%
Max drawdown
-33.6%

Daily closes through 2026-11-17. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for LLY (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.